Article Cited by others

ORIGINAL ARTICLE

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

Wu Kai-Jie, Pei Xin-Qi, Tian Ge, Wu Da-Peng, Fan Jin-Hai, Jiang Yu-Mei, He Da-Lin

Year : 2018| Volume: 20| Issue : 2 | Page no: 173-177

   This article has been cited by
 
1 Biomarkers of response to advanced prostate cancer therapy
Roberto Iacovelli,Chiara Ciccarese,Giovanni Schinzari,Ernesto Rossi,Brigida Anna Maiorano,Serena Astore,Tatiana D’Angelo,Antonella Cannella,Celeste Pirozzoli,Maria Anna Teberino,Francesco Pierconti,Maurizio Martini,Giampaolo Tortora
Expert Review of Molecular Diagnostics. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
2 Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer
Chaojiang Chen,Zhiduan Cai,Yangjia Zhuo,Ming Xi,Zhuoyuan Lin,Funeng Jiang,Zezhen Liu,Yueping Wan,Yu Zheng,Jianxin Li,Xing Zhou,Jianguo Zhu,Weide Zhong
BMC Cancer. 2020; 20(1)
[Pubmed]  [Google Scholar] [DOI]
3 PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium
Xinqi Pei,Kaijie Wu,Yinghao Sun,Xu Gao,Xin Gou,Jun Xu,Fan Gao,Dalin He,Lei Li
Urologic Oncology: Seminars and Original Investigations. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer
Qiang Feng,Peng He,Yu Wang
Gene. 2018; 658: 152
[Pubmed]  [Google Scholar] [DOI]

 

Read this article